Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 1

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 1
---
 “Purchase Agreement”), the Investor will have the right to make a “cashless” exercise of the Warrant and the Company will be required to issue to Investor one (1) ordinary share for every five (5) outstanding Warrant Shares exercised under the Warrant after sending the Company a notice of the breach and an opportunity to cure within five (5) trading days.

This prospectus supplement covers up to 2,000,000 Ordinary Shares, issuable from time to time upon exercise of the Warrant. The Ordinary Shares issuable upon exercise of the Warrant, are being issued pursuant to this prospectus supplement, the accompanying base prospectus, that certain warrant purchase agreement, dated November 26, 2025, by and between the Company and the Investor.

No placement agent is involved in this offering.

Our ordinary shares are listed on the NASDAQ Capital Market under the symbol “EUDA”. On December 3, 2025, the closing price of our ordinary shares on the Nasdaq Capital Market was US$2.86.

There is no established trading market for the Warrant, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Warrant on any national securities exchange or other trading market.

As of the date of this prospectus supplement, the aggregate market value of the voting and non-voting common equity held by non-affiliates, was $71,204,092 (based on the last sales price of $3.89 on October 15, 2025 within 60 days prior to the date hereof and 18,304,394 ordinary shares held by non-affiliates).

Pursuant to General Instruction I.B.5 of Form F-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. During the 12 calendar months prior to and including the date of this prospectus, we have offered and sold convertible notes in the aggregate principal amount of $1,023,615 pursuant to General Instruction I.B.5 of Form F-3.

You should read carefully this prospectus supplement and the documents incorporated by reference in this prospectus supplement before you invest. Please see “Risk Factors” on page S-5 of this prospectus supplement and the risk factors incorporated by reference into this prospectus supplement and the accompanying prospectus for more information.